Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $68.55 USD
Change Today +0.53 / 0.78%
Volume 2.1M
As of 8:04 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Snapshot

Open
$68.38
Previous Close
$68.02
Day High
$68.62
Day Low
$68.00
52 Week High
07/23/14 - $77.31
52 Week Low
02/20/15 - $65.94
Market Cap
37.3B
Average Volume 10 Days
3.9M
EPS TTM
$4.00
Shares Outstanding
543.5M
EX-Date
03/9/15
P/E TM
17.2x
Dividend
$2.08
Dividend Yield
3.03%
Current Stock Chart for BAXTER INTERNATIONAL INC (BAX)

baxter international inc (BAX) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX) Details

Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; and products and services related to pharmacy compounding, drug formulation and packaging technologies, as well as to treat renal disease, irreversible kidney failures, and other renal therapies. This segment also offers products for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, and other dialysis services. It markets its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients. The company operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. It has collaboration with Merrimack Pharmaceuticals, Inc. to develop and commercialize MM-398 injection; CTI BioPharma Corp. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products; and Onconova Therapeutics, Inc. for rigosertib anti-cancer compound. The company was founded in 1931 and is based in Deerfield, Illinois.

66,000 Employees
Last Reported Date: 02/26/15
Founded in 1931

baxter international inc (BAX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $755.0K
Corporate Vice President and President of Bio...
Total Annual Compensation: $833.8K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $651.0K
Corporate Vice President of Human Resources
Total Annual Compensation: $525.3K
Compensation as of Fiscal Year 2014.

baxter international inc (BAX) Key Developments

Baxter International Inc. Amends and Restates its Bylaws

On March 24, 2015, the Bylaws of Baxter International Inc. were amended and restated to remove the mandatory director retirement age from Section 2 Article II. The foregoing description of the amendment and restatement of the Bylaws is qualified in its entirety by reference to the text of the Bylaws, as amended and restated on March 24, 2015.

Baxter Bioscience Announces Positive Phase III Results for BAX 817

Baxter International Inc. announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa (rFVIIa) treatment for people with hemophilia A or B who develop inhibitors. The prospective, open-label, randomized, multicenter trial was designed to assess the safety and efficacy of BAX 817 in male patients ages 12 to 65 with hemophilia A or B with inhibitors over a 6-month period using on-demand therapy. The trial met its primary endpoint of successful resolution of acute bleeding episodes at 12 hours with both on-demand treatment regimens, dosing either 3x90 µg/kg or 1x270 µg/kg, with an overall success rate of 92% (98% and 85% in each dosing group, respectively). Further, 89% of patients in the trial achieved sustained bleeding control for all acute bleeding episodes 24 hours after infusion.

Baxter International Inc. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:00 PM

Baxter International Inc. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:00 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:US $68.55 USD +0.53

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,950 JPY -27.50
CSL Ltd A$91.85 AUD +0.15
Kimberly-Clark Corp $106.37 USD +0.05
Stryker Corp $92.56 USD +1.03
Takeda Pharmaceutical Co Ltd ¥6,111 JPY -134.00
View Industry Companies
 

Industry Analysis

BAX

Industry Average

Valuation BAX Industry Range
Price/Earnings 19.1x
Price/Sales 2.2x
Price/Book 4.5x
Price/Cash Flow 14.8x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.